Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
ITPS Canada Achieves NATO Flight Training Europe Accreditation
Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange and Montreal Exchange Closed for Labour Day
Doubleview Appoints Edward Huebert as Vice President, Permitting, Regulatory & Indigenous Relations
Focus Graphite and C4V to Evaluate Mine-to-Anode Platform Combining Lac Knife Graphite with C4V’s Green Anode Technology
Spritzer Sparkling Invites Malaysians to ‘Reset Rasa’ This Merdeka, Rediscover the Flavours That Unite Us